Analysts gave Zimmer Biomet a mean rating of 2.1 on a scale of one (strong buy) to five (strong sell), according to CWRU Observer.
Here are four things to know:
1. Nine analysts rated the stock "buy," 10 analysts rated it "outperform" and 10 analysts rated it "hold."
2. Analysts gave a consensus estimate of $1.93 share, which compares with $1.58 the same quarter last year.
3. Wall Street analysts predict Zimmer Biomet will see an annual growth of about 10.69 percent over the next five years.
4. Some analysts predict the 12-month average price target will hit $150, while others predict it will reach $120.71.